Christopher McCarthy - 20 Aug 2026 Form 4 Insider Report for INTERPACE BIOSCIENCES, INC. (IDXG)

Reporting relationship: CFO & COO
Issuer ticker: IDXG
Reported as of: 20 Aug 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 20 Aug 2026, 16:59:02 UTC
Prior SEC filing: 06 Feb 2024
Source filing: View source filing
Reporting owner signature: /s/ Christopher McCarthy

Key filing fact

Christopher McCarthy filed Form 4 for INTERPACE BIOSCIENCES, INC. (IDXG) on 20 Aug 2026.

Key facts

This page summarizes Christopher McCarthy's Form 4 filing for INTERPACE BIOSCIENCES, INC. (IDXG).
4 reported transactions and 3 derivative rows are listed below.
Accepted by SEC: 20 Aug 2026, 16:59.

Change

Previous filing in this sequence was filed on 06 Feb 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001975031 Primary reporting owner

McCarthy Christopher

Relationship: CFO & COO
Address: C/O INTERPACE BIOSCIENCES, INC., 2001 ROUTE 46 WATERVIEW PLAZA, SUITE 310, PARSIPPANY
Signature: /s/ Christopher McCarthy
Signature date: 20 Aug 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

IDXG transaction

Common Stock

Options Exercise

Transaction value
Shares: +277,009
Change %: +592%
Price: $0.000000^*
Shares after: 323,800
Date: 20 Aug 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IDXG transaction Derivative

Restricted Stock Units

Award

Transaction value
Shares: +554,018
Change %
Price: $0.000000^*
Shares after: 554,018
Date: 20 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 554,018
Exercise price
Footnotes: F2, F3

IDXG transaction Derivative

Restricted Stock Units

Options Exercise

Transaction value
Shares: -277,009
Change %: -50%
Price: $0.000000^*
Shares after: 277,009
Date: 20 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 277,009
Exercise price
Footnotes: F2, F3

IDXG transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +277,009
Change %
Price: $0.000000^*
Shares after: 277,009
Date: 20 Aug 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 277,009
Exercise price: $2.02
Footnotes: F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Represents the conversion upon vesting of restricted stock units (RSUs) into shares of common stock of Interpace Biosciences, Inc. On August 20, 2026, the Reporting Person was granted 554,018 RSUs, of which 277,009 vested upon grant and 277,009 will vest on August 20, 2027, subject to the Reporting Person's continued service on such vesting date.

Footnote F2

Each RSU represents a contingent right to receive the economic equivalent of one share of common stock of Interpace Biosciences, Inc.

Footnote F3

On August 20, 2026, the Reporting Person was granted 554,018 RSUs, of which 277,009 vested upon grant and 277,009 will vest on August 20, 2027, subject to the Reporting Person's continued service on such vesting date.

Footnote F4

The options will vest in four equal annual installments beginning on August 20, 2027, subject to the Reporting Person's continued service on each such vesting date.